www.00kcd.com_www.00kcd.com-【成立至今】

来源:天安门观礼台等入选北京市第二批历史建筑名单  作者:   发表时间:2019-11-15 06:07:45

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

编辑:www.00kcd.com_www.00kcd.com-【成立至今】

未经授权许可,不得转载或镜像
© Copyright © 1997-2017 by yunjianguo.com all rights reserved

百站百胜: 禁渔期捕海参长到半截就贱卖?这家公司真急了… 陈慧:5G可能更进一步地赋能大家生活品质的提升 新能源车企勒紧裤腰带呼吁限购解禁等刺激政策落实 联合国儿童基金会:儿童应该参与互联网政策的制定 全面权威解读如何看外资银行及保险管理条例新修订? 京沪高铁上市招股书:去年净利超百亿资产负债率14% 日本小车撞入咖啡馆致9伤75岁肇事者被当场逮捕 科创板本周交易满3月股价进入价值回归阶段 儿基会:也门冲突造成5000余名儿童伤亡 东北亚经济论坛成功举办:高水平开发助力东北振兴 普惠金融指标分析报告:我国普惠金融继续稳步发展 央行今日开展600亿元逆回购操作净投放600亿 华为债获3倍认购:百亿资金疯抢利率3.48%堪比央企 水究竟从哪里来?或要一直追溯到宇宙起源时期 黑龙江通报恶意举报有人对岗位不满想 刘鹤:坚持底线思维确保今年清欠任务全面完成 51信用卡创始人孙海涛致歉:优先确保出借人如期兑付 9个粮食原产地荣获“特色产业县市”称号 JamesDick:艺人永远第一位每年赞助艺人60亿美元 因入住率低WeWork正寻求关闭中国的办公空间 2019两岸企业家紫金山峰会年会11月3至5日在南京举办 每经评论员:企业成了家庭财产李国庆俞渝注定无果 微软净利增21%背后:Azure营收增速连续八季下滑 外交部副部长乐玉成:中国不会放弃自己成功的道路 中青报发声:缺乏基本常识“爱国”反而“害国” 食品拉动CPI“撞3”调控要多管齐下 中国队收获军运会乒乓球首枚金牌 科创板公司“含科率”获点赞包容性将持续提升 北京将制定《北京市优化营商环境条例》 智能音箱概念股走强共达电声涨停 上市公司并购重组升温受理审核提速过会率近九成 数读“第六届世界互联网大会” 白酒股今年表现气势如虹布局白酒需了解三类品种 林毅夫:发展经济学的范式转移与新结构经济学 拜登竞选网站遭“劫持”链接指向特朗普竞选网站 欧美决策层对经济放缓反应克制或令衰退成为现实 茂化实华“宫斗”新进展:刘军之妻重获授权委托 在线信用卡“管家”股价跌逾30%有A股公司被拖累 安徽昨天召开一个重要会议省委书记省长答记者问 人民日报谈詹姆斯遭围攻:让我们见识“双重标准” 杨伟民:提升城乡消费能力须克服城市化过程四个失衡 贝莱德CEO谈投资环境:不算好但也没感觉那么糟 叙政府军“完全控制”北部重镇曼比季美军已撤出 澳大利亚超市现“肉片藏针”一8旬女子险些吞下 12年前6124点买的基金如今有一批赚100%以上(名单) 民政部回应民生热点问题初心不改为人民 中信证券狂卖中信建投8个亿还有更多“卖盘”在路上 蒙牛低调试水新品牌“甄简”加快布局大健康产业 博汇科技确定转战科创板赊销与退税增利较突出 沙特阿美从国外油企中获利单薄将对此领域巨额投资 广西玉林化工厂爆炸:铁皮飞入驾校考场划伤监考官 美官员编造专家攻击中国外交部:做人要有底线 国家网络安全产业园区(海淀)挂牌已有29家企业入驻 距利率决议不到两周美联储对进一步降息持开放态度 海信新机入网工信部:4850mAh电池+后置四摄 iPhone12ProMax曝光:6000mAh石墨烯电池+A14芯 高盛:预计美团点评三季度业绩稳固稍胜市场预期 媒体解读12条外汇管理新措施:简化取消和放开 港股傲迪玛汽车上市3天涨7倍内资为最大炒作资金 世预赛国足客场0:0菲律宾历史首次战平对手 车贷的坑,你了解多少? 海口发文严禁捆绑销售、变相加价等行为 隆基股份:拟公开发行不超50亿元可转债 发批评文章的女教师李田田:课程减半外出需汇报 2019年《财富》未来50强揭晓:16家中国公司上榜 英媒:特朗普私人律师承认拿过乌裔商人50万美元 百度:飞桨深度学习平台已累计服务150多万开发者 教育部规定军事课列入教学计划实行学分制管理 勾肩搭背握手言欢英首相成欧盟峰会现场“红人” 伊拉克多地爆发新一轮示威已造成示威者2死67伤 推特发一篇声明又让特朗普成为舆论关注焦点 证监会%构建中长期资金 冬春航季启动多家航企正式入场北京大兴机场运营 瑞典央行行长:Libra数字货币是改革的催化剂 税友集团IPO:实控人边行贿边做公益蚂蚁金服曾入股 维达国际第三季经营溢利大幅增长194.4% 高盛:华泰证券维持买入评级目标价15.58港元 P2P平台出路何在?清退仍为行业主旋律 刘鹤:加强知识产权保护特别是中小企业知识产权保护 工业大麻概念股异动拉升云天化直线涨停 上海交通事故致2死12伤司机未排除酒驾毒驾嫌疑 优信获国际知名投资机构GIC举牌持股比例达5.01% 华南首批券商大集合公募化转型两只产品近日获批 “退二进一”特朗普这步棋走得好纠结 江西多地发布“麻将馆禁令”:取缔营业性麻将馆 “雪龙2”号首次穿越赤道进入南半球 在资金告罄、破产清算之前答应了软银 (受权发布)中华人民共和国国务院令第720号 姜岩:二十载春华秋实重整行装再出发 内幕交易鸡飞蛋打:停牌前突击买入亏135万还罚30万 德国5G网络将确认不排除使用华为设备 10月23日现货黄金、白银、原油、外汇短线交易策略 秦洪看盘:强势股倒戈市场低估值品种奋起护盘 第二颗星际天体到访 重组新规修订发布符合条件资产可在创业板重组上市 10月25日复盘:下周迎反弹行情主力出击14股 河北省上市公司首家3季报出炉金牛化工净利2460万元 港股通(沪)净流入4.06亿港股通(深)净流入5.06亿 任正非:现在限制华为终端用谷歌软件无关国家安全 三全食品2019年前三季度收入停滞现金流萎缩278% 赴港IPO:上市筹备时间短成功率高首发市盈率低于A股 欧盟代表:欧盟和英国须15日午夜敲定脱欧协议文案 特鲁多竞选中呼吁:我们需要强大的政府抵抗特朗普 伊朗石油部长:美制裁未能遏制本国石油工业发展 未充分披露重大事项等“新鼎明系”私募再吃监管函 直通电讯料9个月业绩盈转亏 减持规则调整预期升温:质押风险等“副作用”迎重估 科创板安恒信息:发行价确定为56.50元/股 前三季度央企实现净利润10567亿元同比增长7.4% 央行要求银行自查三方数据公司合作是否涉及爬虫 冬供消费旺季临近液化天然气市场价格开启连涨模式 易纲:央行将继续实施稳健的货币政策 乐视网:贾跃亭宣称要还债但公司未获任何现金 韩媒称中国航司待遇优厚吸引大批韩国飞行员跳槽 全国人大财政经委委员:支持外贸新业态在科创板上市 新能源车企勒紧裤腰带呼吁限购解禁等刺激政策落实 铁货首9个月K&S生产铁精矿增加10.5% 徐玉良:在推进企业精益化管理过程中应重视人才培养 易纲:中国绿色金融市场发展迅速、潜力巨大 百年人寿被查副总回应:范围仅有山东河南两家分公司 印尼巴布亚省发生5.2级地震震源深度10千米 英首相月底“脱欧”计划落空OPEC考虑12月深化减产 同一境外主体QFII/RQFII和直接入市债券可非交易过户 ST康美:控股股东的一致行动人终止实施增持计划 净利润同比下滑26%亚马逊朝万亿市值越“跑”越远? 正邦科技第三季净利超3亿完全覆盖上半年亏损 平安基金增聘两基金经理吕振山和成钧“新手”上阵 央行报告:去年全国有近48%成年人购买过投资理财产品 美国数十名共和党议员“硬闯”弹劾调查听证会 途牛旅游陷“投诉门”:年内遭消费者起诉已败诉五场 美股盘前:欧央行维持利率不变美期指攀升 致癌风波频频,强生公司消费品板块受诉讼拖累 以媒:不甘心失败内塔尼亚胡给甘茨组阁设障碍 51信用卡遭调查西湖区要求P2P平台年底余额再降25% 创维海尔等7家被约谈:开机广告不应成“标配” 欧盟与英国谈判代表据称已接近达成脱欧协议草案 主动撤军后美军出动战机摧毁留在叙利亚的弹药库 诺诚健华上市冲施一公家族身家或近10亿 午评:沪股通净流入2.7亿深股通净流入15.53亿 快讯:子公司杰克沃克拟申请破产清算拉夏贝尔跌14% 警方协调吉翔股份董事长与郑龙云冲突:互致歉(视频) 前9月我国对外承包工程完成营业额6998亿同比降2.8% 强降雨导致印度南部13人死亡 工商银行三季报出炉:日均赚9.3亿不良连降11季度 60万参投《哪吒》获利1800万?片方回应:假的 北京限竞房土地供应增加:库存达峰值项目成交分化 处于试验阶段的“空中汽车”来了或实现人脑操控 扎克伯格向国会作证:天秤币可提高美国金融领导地位 并购重组新规落地小市值板块中长期投资机会或来临 库尔德人让出更多城市叙利亚政府军接管美军军营 世诚投资:未来可能流入A股的外资有望到6000亿美元 罕见大罚单!500多亿违规中国银行两分行被罚5150万 WeWork创始人将彻底离开公司获约17亿美元补偿 贝因美改名:房屋租赁咋也成主营业务改名能否改运? 期债易跌难涨 特朗普狠批党内反对者:小心点他们是人渣 “吃货贼”不识货偷走价值万元观赏鱼做鱼生片 耿爽对美国提出了一个灵魂拷问 温氏股份前三季净利增110%陆股通:十大流通股东之首 沪指收阳险守60日线创业板壳概念股掀涨停潮 农业农村部:上半年生猪扑杀补助资金近期将下拨各地 智利警车街头碾压一名抗议者致其死亡 他逆转夺冠后一个动作让全场尖叫沸腾 特斯拉市值暴增90亿美元再度超越通用 微软高管:SurfaceDuo最适合的操作系统是Android “双11”临近:两家公司涨价备战快递板块会爆发吗? 临港将编制综合能源规划实现企业生产成本最小化 特朗普与两位女宇航员通话说错话被当场纠正 人民日报海外版:网络亚文化不该传递负能量 评论:电商平台“二选一”是反市场行为 英国示威活动加剧政府要求警方“严厉镇压” 美宣布捣毁最大儿童色情暗网:用户用比特币交易 英国集装箱藏尸案:警方再逮捕一男一女 大学生身体素质呈下降趋势体育“挂科”难毕业 消息称证监中层干部大调整推动监管流程再造 英镑回落脱欧谈判今日继续关注晚间“恐怖数据” 俄罗斯鸟类保护研究团队濒临“破产”原因很离奇 中环装备多业务发力三季报预喜研发投入增逾六成 “阿胶”变“马皮胶”?半数阿胶查出马皮成分 议会通过Letwin修正案英国将再度延迟脱欧 快讯:环保工程板块拉升神雾环保触板 美B52模拟轰炸克里米亚俄警告:S400让你有来无回 9月挖掘机销量高歌猛进市场普遍较为乐观 小米的“焦虑”:浪潮褪去小米是否在“裸泳”? 媒体:NBA球员詹姆斯和香港之间存在一个关键事实 我是如何被淘集集拖垮的 伊朗外长:红海油轮被袭击背后有一个或者多个国家 世行报告显示中国营商环境排名大幅提升 男子一气之下把自己家点燃18万家当全部烧光(图) 燕郊定向放松限购?不动产登记大厅:仍执行原政策 华菁证券某负责人:未来两三年是资本市场发展黄金期 即日生效!办理住房公积金提取将不再需纸质申请书 科创板拟上市公司二十一世纪空间技术终止注册 广州南沙:推进设立粤港澳大湾区国际商业银行 新京报:云南普洱打击电信诈骗封号不应伤及无辜 中国海警缉毒画面曝光惊险程度有如大片 波司登现涨近4%突破10天线